Evidence map›Paper›PMID 40463545›Full record

ArticlemedRxiv : the preprint server for health sciences2025

GWAS identifies genetic loci for antibody response to SARS-CoV-2 vaccines in patients with systemic autoimmune diseases and healthy individuals.

Kwangwoo Kim, Dillon Claybaugh, Eduardo Patino-Martinez, Yenealem Temesgen-Oyelakin, Elaine Poncio, Jun Chu, Michael Davis, Alice Fike, Yanira Ruiz-Perdomo, Julie Onyechi and 27 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors.

Kwangwoo KimDepartment of Biology, Kyung Hee University, Seoul, Republic of Korea.ORCID 0000-0001-8926-6216
Dillon ClaybaughNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Eduardo Patino-MartinezNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Yenealem Temesgen-OyelakinNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Elaine PoncioNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Jun ChuNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Michael DavisNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Alice FikeNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Yanira Ruiz-PerdomoNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Julie OnyechiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Margaret BeachNational Institute of Dental and Craniofacial Research (NIDCR).
Lilian HowardNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Eileen PelayoNational Institute of Dental and Craniofacial Research (NIDCR).
Nancy SpencerNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Martha SullyOffice of Research Support & Compliance; NIH Clinical Center.
Rita VolochayevNational Institute of Environmental Health Sciences (NIEHS).
Sophie KellyNational Institute of Biomedical Imaging and Bioengineering (NIBIB).
Sarah PorcheNational Institute of Biomedical Imaging and Bioengineering (NIBIB).
Laura B LewandowskiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).ORCID 0000-0002-4253-2545
Luis M FrancoNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).ORCID 0000-0002-0540-5942
Zerai MannaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Sarthak GuptaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).ORCID 0000-0001-8255-3554
Amy HutchinsonCancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Rockville, MD.
Lisa MirabelloDivision of Cancer Epidemiology and Genetics, National Cancer Institute (NCI); National Institutes of Health, Bethesda, MD, USA.
Vibha VijDivision of Cancer Epidemiology and Genetics, National Cancer Institute (NCI); National Institutes of Health, Bethesda, MD, USA.
Kaitlin A QuinnNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Peter C GraysonNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Adam SchiffenbauerNational Institute of Environmental Health Sciences (NIEHS).
Lisa G RiderNational Institute of Environmental Health Sciences (NIEHS).
Iago Pinal-FernandezNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).ORCID 0000-0001-6338-9218
Andrew L MammenNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Heather R KalishNational Institute of Biomedical Imaging and Bioengineering (NIBIB).
Meryl A WaldmanNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Blake WarnerNational Institute of Dental and Craniofacial Research (NIDCR).
Sarfaraz HasniNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute (NCI); National Institutes of Health, Bethesda, MD, USA.
Mariana J KaplanNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
NCI NIH HHS 75N91019D00024Wellcome Trust
6 · The paper itself

Abstract

The efficacy of nucleic acid-based vaccines against SARS-CoV-2 varies across individuals, partly due to genetic factors influencing neutralizing antibody production. In patients with systemic autoimmune diseases (SADs), this response may be further altered by immune dysregulation. We conducted a genome-wide association study (GWAS) to identify genetic variants associated with post-vaccination anti-SARS-CoV-2 IgG antibody levels and to assess whether these associations differ between SAD patients and healthy individuals. The study included 165 participants (138 with SADs, 27 healthy controls), all of whom received nucleic-acid based vaccines. Antibody levels targeting the spike protein receptor-binding domain (RBD) and nucleocapsid were measured between one and twelve months after vaccination. GWAS results were meta-analyzed with data from a previously published GWAS of 1,076 healthy individuals. We identified a novel association near

Identifiers

PMID40463545
PMCPMC12132131

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.